Breaking News Instant updates and real-time market news.

FTSI

FTS International

$3.28 /

-0.02 (-0.61%)

17:06
11/05/20
11/05
17:06
11/05/20
17:06

FTS International announces successful confirmation of reorganization plan

FTS International announced that the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division has confirmed its Prepackaged Plan of Reorganization. Under the terms of the Confirmed Plan, which was approved at a hearing on November 4, 2020, the Company accomplished the elimination of all of its prepetition funded debt, approximately $437 million. Importantly, the Confirmed Plan ensures that the Company's vendors, suppliers, and customers will remain unaffected by the reorganization. The Company's existing equity holders will also receive a recovery under the Confirmed Plan. Additionally, on November 3, 2020, the Company settled its dispute with Covia Holdings Corporation. "I am pleased to have reached an agreement with all parties involved and look forward to emerging from Chapter 11 in the next couple of weeks," said Michael Doss, Chief Executive Officer of FTSI. "The overwhelming support by all parties involved and confirmation by the court will allow FTSI to emerge from the process debt-free and in an ideal position to navigate the current environment and take advantage of future opportunities. I appreciate our customers, our vendors, and our employees for working through this process with us and am excited that FTSI will be better positioned than ever before and continue being a leader in the well completions space."

FTSI FTS International
$3.28 /

-0.02 (-0.61%)

03/19/20 Barclays
FTS International downgraded to Underweight from Equal Weight at Barclays
03/17/20 Evercore ISI
FTS International downgraded to Underperform from Outperform at Evercore ISI
03/16/20 Morgan Stanley
FTS International downgraded to Underweight from Overweight at Morgan Stanley
03/13/20 Wells Fargo
Drillers downgraded at Wells Fargo on recent sell off in commodity prices

TODAY'S FREE FLY STORIES

Hot Stocks
Enochian Biosciences announces FDA acceptance of pre-IND for potential HIV cure » 07:23
06/14/21
06/14
07:23
06/14/21
07:23
ENOB

Enochian Biosciences

$4.38 /

-0.02 (-0.45%)

Enochian BioSciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ENOB Enochian Biosciences
$4.38 /

-0.02 (-0.45%)

ENOB Enochian Biosciences
$4.38 /

-0.02 (-0.45%)

Initiation
Procore initiated with an Overweight at JPMorgan » 07:21
06/14/21
06/14
07:21
06/14/21
07:21
PCOR

Procore

$83.98 /

-2.47 (-2.86%)

JPMorgan analyst Sterling…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PCOR Procore
$83.98 /

-2.47 (-2.86%)

07:04 Today William Blair
Procore initiated with an Outperform at William Blair
06:21 Today Canaccord
Procore initiated with a Buy at Canaccord
06:15 Today Oppenheimer
Procore initiated with an Outperform at Oppenheimer
06:09 Today Piper Sandler
Procore initiated with an Overweight at Piper Sandler
  • 20
    May
PCOR Procore
$83.98 /

-2.47 (-2.86%)

PCOR Procore
$83.98 /

-2.47 (-2.86%)

Hot Stocks
iTeos Therapeutics, GlaxoSmithKline collaborate for EOS-448 » 07:21
06/14/21
06/14
07:21
06/14/21
07:21
ITOS

iTeos Therapeutics

$20.01 /

+0.11 (+0.55%)

, GSK

GlaxoSmithKline

$40.15 /

-0.07 (-0.17%)

iTeos Therapeutics (ITOS)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ITOS iTeos Therapeutics
$20.01 /

+0.11 (+0.55%)

GSK GlaxoSmithKline
$40.15 /

-0.07 (-0.17%)

ITOS iTeos Therapeutics
$20.01 /

+0.11 (+0.55%)

05/19/21 SVB Leerink
iTeos Therapeutics price target lowered to $45 from $60 at SVB Leerink
05/14/21 Piper Sandler
iTeos Therapeutics recent pullback unwarranted, says Piper Sandler
05/05/21 H.C. Wainwright
iTeos Therapeutics initiated with a Buy at H.C. Wainwright
04/12/21 Piper Sandler
iTeos Therapeutics' EOS-448 'competitive' in TIGIT class, says Piper Sandler
GSK GlaxoSmithKline
$40.15 /

-0.07 (-0.17%)

06/11/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,300 GBp at Deutsche Bank
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
ITOS iTeos Therapeutics
$20.01 /

+0.11 (+0.55%)

GSK GlaxoSmithKline
$40.15 /

-0.07 (-0.17%)

  • 24
    Jul
GSK GlaxoSmithKline
$40.15 /

-0.07 (-0.17%)

GSK GlaxoSmithKline
$40.15 /

-0.07 (-0.17%)

GSK GlaxoSmithKline
$40.15 /

-0.07 (-0.17%)

Recommendations
PDC Energy price target raised to $65 from $51 at JPMorgan » 07:20
06/14/21
06/14
07:20
06/14/21
07:20
PDCE

PDC Energy

$47.79 /

+0.6 (+1.27%)

JPMorgan analyst Arun…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PDCE PDC Energy
$47.79 /

+0.6 (+1.27%)

PDCE PDC Energy
$47.79 /

+0.6 (+1.27%)

02/25/21 JPMorgan
PDC Energy price target raised to $47 from $30 at JPMorgan
01/21/21 JPMorgan
PDC has roadmap to narrow discount to intrinsic value, says JPMorgan
01/21/21 Citi
PDC Energy price target raised to $30 from $21 at Citi
01/19/21 Cowen
PDC Energy price target raised to $33 from $27 at Cowen
PDCE PDC Energy
$47.79 /

+0.6 (+1.27%)

Initiation
Halozyme initiated with an Outperform at Evercore ISI » 07:20
06/14/21
06/14
07:20
06/14/21
07:20
HALO

Halozyme

$42.82 /

+1.09 (+2.61%)

Evercore ISI analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HALO Halozyme
$42.82 /

+1.09 (+2.61%)

HALO Halozyme
$42.82 /

+1.09 (+2.61%)

06/11/21 BMO Capital
Halozyme coverage transferred at BMO Capital
05/17/21 SVB Leerink
Halozyme initiated with an Outperform at SVB Leerink
05/17/21 SVB Leerink
Halozyme initiated with an Outperform at SVB Leerink
05/11/21 Piper Sandler
Halozyme downgraded to Neutral from Overweight at Piper Sandler
HALO Halozyme
$42.82 /

+1.09 (+2.61%)

HALO Halozyme
$42.82 /

+1.09 (+2.61%)

Initiation
Ingersoll-Rand reinstated with a Neutral at Credit Suisse » 07:19
06/14/21
06/14
07:19
06/14/21
07:19
IR

Ingersoll-Rand

$47.92 /

+0.52 (+1.10%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IR Ingersoll-Rand
$47.92 /

+0.52 (+1.10%)

IR Ingersoll-Rand
$47.92 /

+0.52 (+1.10%)

05/19/21 Deutsche Bank
Deutsche Bank upgrades 'laggard' Ingersoll-Rand to Buy
05/19/21 Deutsche Bank
Ingersoll-Rand upgraded to Buy from Hold at Deutsche Bank
05/12/21 Evercore ISI
Ingersoll-Rand price target raised to $53 from $48 at Evercore ISI
04/06/21 Barclays
Ingersoll-Rand price target raised to $56 from $53 at Barclays
IR Ingersoll-Rand
$47.92 /

+0.52 (+1.10%)

  • 11
    May
  • 17
    Jun
IR Ingersoll-Rand
$47.92 /

+0.52 (+1.10%)

IR Ingersoll-Rand
$47.92 /

+0.52 (+1.10%)

Upgrade
Krung Thai Bank upgraded to Neutral from Underweight at JPMorgan » 07:19
06/14/21
06/14
07:19
06/14/21
07:19
KTHAF

Krung Thai Bank

/

+

JPMorgan analyst Harsh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KTHAF Krung Thai Bank
/

+

09/09/20 Goldman Sachs
Krung Thai Bank upgraded to Neutral from Sell at Goldman Sachs
Hot Stocks
Global Blood Therapeutics receives PIM designation for voxelotor from UK » 07:17
06/14/21
06/14
07:17
06/14/21
07:17
GBT

Global Blood Therapeutics

$40.64 /

-1.01 (-2.42%)

Global Blood Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

Recommendations
Eli Lilly price target raised to $270 from $252 at Goldman Sachs » 07:17
06/14/21
06/14
07:17
06/14/21
07:17
LLY

Eli Lilly

$224.12 /

-9.42 (-4.03%)

, BIIB

Biogen

$396.46 /

-18.29 (-4.41%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
05/27/21 H.C. Wainwright
H.C. Wainwright bullish on Dicerna as new RNAi candidate enters clinic
05/24/21 H.C. Wainwright
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
BIIB Biogen
$396.46 /

-18.29 (-4.41%)

07:14 Today Goldman Sachs
Biogen price target raised to $436 from $246 at Goldman Sachs
06/11/21
Fly Intel: Top five analyst upgrades
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
06/11/21 RBC Capital
Prothena price target raised to $50 from $28 at RBC Capital
LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

Initiation
Oatly Group initiated with a Buy at Truist » 07:15
06/14/21
06/14
07:15
06/14/21
07:15
OTLY

Oatly Group

$28.71 /

+2.01 (+7.53%)

Truist analyst Bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

07:02 Today William Blair
Oatly Group initiated with an Outperform at William Blair
06:36 Today Guggenheim
Oatly Group initiated with a Buy at Guggenheim
06:24 Today Truist
Oatly Group initiated with a Buy at Truist
06:17 Today Oppenheimer
Oatly Group initiated with a Perform at Oppenheimer
  • 20
    May
OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

OTLY Oatly Group
$28.71 /

+2.01 (+7.53%)

Hot Stocks
Boxed to become US publicly traded company through merger with Seven Oaks SPAC » 07:14
06/14/21
06/14
07:14
06/14/21
07:14
SVOK

Seven Oaks Acquisition

$9.81 /

+0.06 (+0.62%)

Boxed, an e-commerce…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SVOK Seven Oaks Acquisition
$9.81 /

+0.06 (+0.62%)

Recommendations
Biogen price target raised to $436 from $246 at Goldman Sachs » 07:14
06/14/21
06/14
07:14
06/14/21
07:14
BIIB

Biogen

$396.46 /

-18.29 (-4.41%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BIIB Biogen
$396.46 /

-18.29 (-4.41%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

06/11/21
Fly Intel: Top five analyst upgrades
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
06/11/21 RBC Capital
Prothena price target raised to $50 from $28 at RBC Capital
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
BIIB Biogen
$396.46 /

-18.29 (-4.41%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

Hot Stocks
Avenue Therapeutics receives complete response letter from FDA for IV tramadol » 07:10
06/14/21
06/14
07:10
06/14/21
07:10
ATXI

Avenue Therapeutics

$4.23 /

-0.14 (-3.20%)

Avenue Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATXI Avenue Therapeutics
$4.23 /

-0.14 (-3.20%)

ATXI Avenue Therapeutics
$4.23 /

-0.14 (-3.20%)

04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
03/01/21 H.C. Wainwright
InvaGen takeout 'may still be in play' at Avenue, says H.C. Wainwright
02/17/21 Dawson James
Fortress Biotech price target raised to $21 from $16 at Dawson James
10/12/20 H.C. Wainwright
Avenue downgraded to Neutral on merger uncertainty at H.C. Wainwright
ATXI Avenue Therapeutics
$4.23 /

-0.14 (-3.20%)

Recommendations
Ascendis's TransCon GH still likely to gain approval, says Cantor Fitzgerald » 07:10
06/14/21
06/14
07:10
06/14/21
07:10
ASND

Ascendis Pharma

$130.26 /

+1.7 (+1.32%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASND Ascendis Pharma
$130.26 /

+1.7 (+1.32%)

ASND Ascendis Pharma
$130.26 /

+1.7 (+1.32%)

06:28 Today Morgan Stanley
Ascendis Pharma price target lowered to $197 from $201 at Morgan Stanley
06/01/21 Canaccord
Ascendis Pharma price target raised to $196 from $190 at Canaccord
05/26/21 JPMorgan
Ascendis should be bought into second half catalysts, says JPMorgan
05/11/21 JPMorgan
Ascendis shares offer 'very compelling entry point,' says JPMorgan
ASND Ascendis Pharma
$130.26 /

+1.7 (+1.32%)

  • 08
    Jul
Hot Stocks
Moderna submits application to Swissmedic for COVID-19 vaccine in adolescents » 07:10
06/14/21
06/14
07:10
06/14/21
07:10
MRNA

Moderna

$218.69 /

+1.59 (+0.73%)

Moderna announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$218.69 /

+1.59 (+0.73%)

MRNA Moderna
$218.69 /

+1.59 (+0.73%)

06/10/21 Piper Sandler
Moderna should be vaccinating teens this summer, says Piper Sandler
06/07/21 Piper Sandler
Moderna price target raised to $246 from $231 at Piper Sandler
05/21/21 Piper Sandler
Piper says overseas approvals providing 'second leg of growth' for Moderna
05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
MRNA Moderna
$218.69 /

+1.59 (+0.73%)

MRNA Moderna
$218.69 /

+1.59 (+0.73%)

MRNA Moderna
$218.69 /

+1.59 (+0.73%)

MRNA Moderna
$218.69 /

+1.59 (+0.73%)

Recommendations
Equinix price target raised to $920 from $850 at Deutsche Bank » 07:10
06/14/21
06/14
07:10
06/14/21
07:10
EQIX

Equinix

$815.71 /

-7.35 (-0.89%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQIX Equinix
$815.71 /

-7.35 (-0.89%)

EQIX Equinix
$815.71 /

-7.35 (-0.89%)

06/07/21 MoffettNathanson
QTS Realty buyout 'very appealing result,' says MoffettNathanson
04/29/21 Barclays
Equinix price target raised to $867 from $861 at Barclays
04/27/21 Barclays
Equinix price target lowered to $861 from $869 at Barclays
04/22/21 Credit Suisse
Equinix price target lowered to $936 from $942 at Credit Suisse
EQIX Equinix
$815.71 /

-7.35 (-0.89%)

EQIX Equinix
$815.71 /

-7.35 (-0.89%)

EQIX Equinix
$815.71 /

-7.35 (-0.89%)

Hot Stocks
Athira Pharma appoints Rachel Lenington as Chief Technology Officer » 07:09
06/14/21
06/14
07:09
06/14/21
07:09
ATHA

Athira Pharma

$19.74 /

-0.12 (-0.60%)

, SGEN

Seagen

$156.27 /

-2.3 (-1.45%)

Athira Pharma (ATHA)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATHA Athira Pharma
$19.74 /

-0.12 (-0.60%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

ATHA Athira Pharma
$19.74 /

-0.12 (-0.60%)

06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
06/07/21 Jefferies
Athira Pharma could rise 25-50% in short-term after Biogen news, says Jefferies
10/13/20 Jefferies
Athira Pharma initiated with a Buy at Jefferies
SGEN Seagen
$156.27 /

-2.3 (-1.45%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
ATHA Athira Pharma
$19.74 /

-0.12 (-0.60%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

  • 21
    Jan
  • 18
    Sep
ATHA Athira Pharma
$19.74 /

-0.12 (-0.60%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

ATHA Athira Pharma
$19.74 /

-0.12 (-0.60%)

Initiation
Marqeta initiated with an Outperform at Autonomous » 07:09
06/14/21
06/14
07:09
06/14/21
07:09
MQ

Marqeta

$31.50 /

+1.85 (+6.24%)

Autonomous analyst Craig…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 09
    Jun
MQ Marqeta
$31.50 /

+1.85 (+6.24%)

Hot Stocks
Legion Partners issues letter to Genesco » 07:09
06/14/21
06/14
07:09
06/14/21
07:09
GCO

Genesco

$62.21 /

+3.2 (+5.42%)

Legion Partners Asset…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GCO Genesco
$62.21 /

+3.2 (+5.42%)

GCO Genesco
$62.21 /

+3.2 (+5.42%)

05/19/21 Pivotal Research
Genesco price target raised to $65 from $57 at Pivotal Research
01/12/21 Pivotal Research
Genesco price target raised to $43 from $37 at Pivotal Research
01/11/21 CL King
Genesco's quarter-to-date comps ahead of estimates, says CL King
12/08/20 Jefferies
Deckers Brands price target raised to $346 from $315 at Jefferies
GCO Genesco
$62.21 /

+3.2 (+5.42%)

Recommendations
Eastman Chemical price target raised to $140 from $132 at Deutsche Bank » 07:09
06/14/21
06/14
07:09
06/14/21
07:09
EMN

Eastman Chemical

$124.58 /

+0.31 (+0.25%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EMN Eastman Chemical
$124.58 /

+0.31 (+0.25%)

EMN Eastman Chemical
$124.58 /

+0.31 (+0.25%)

06/09/21 Wolfe Research
Eastman Chemical initiated with an Outperform at Wolfe Research
05/11/21 Goldman Sachs
Eastman Chemical upgraded to Buy from Neutral at Goldman Sachs
05/03/21 KeyBanc
Eastman Chemical price target raised to $135 from $126 at KeyBanc
03/16/21 Deutsche Bank
Eastman Chemical price target raised to $126 from $115 at Deutsche Bank
EMN Eastman Chemical
$124.58 /

+0.31 (+0.25%)

EMN Eastman Chemical
$124.58 /

+0.31 (+0.25%)

Hot Stocks
Forma Therapeutics appoints John Bishop as CTO » 07:08
06/14/21
06/14
07:08
06/14/21
07:08
FMTX

Forma Therapeutics

$22.81 /

-5.2 (-18.56%)

, EPZM

Epizyme

$8.53 /

+0.08 (+0.95%)

Forma Therapeutics (FMTX)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

  • 11
    Dec
  • 19
    Jun
EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

Recommendations
Snowflake price target raised to $265 from $248 at Deutsche Bank » 07:08
06/14/21
06/14
07:08
06/14/21
07:08
SNOW

Snowflake

$240.83 /

-7.96 (-3.20%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNOW Snowflake
$240.83 /

-7.96 (-3.20%)

SNOW Snowflake
$240.83 /

-7.96 (-3.20%)

06/11/21 Morgan Stanley
Morgan Stanley says 'unprecedented' Snowflake forecast may still be conservative
06/11/21 JMP Securities
Snowflake target model calls for $10B in revenue by FY29, says JMP Securities
06/11/21 Piper Sandler
Snowflake price target lowered to $290 from $312 at Piper Sandler
06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
SNOW Snowflake
$240.83 /

-7.96 (-3.20%)

  • 16
    Mar
  • 16
    Sep
SNOW Snowflake
$240.83 /

-7.96 (-3.20%)

SNOW Snowflake
$240.83 /

-7.96 (-3.20%)

Periodicals
Shopify, Sequoia buy Stripe shares, WSJ reports » 07:07
06/14/21
06/14
07:07
06/14/21
07:07
SHOP

Shopify

$1,247.70 /

+14.17 (+1.15%)

Shopify, Sequoia Capital…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SHOP Shopify
$1,247.70 /

+14.17 (+1.15%)

SHOP Shopify
$1,247.70 /

+14.17 (+1.15%)

06:12 Today RBC Capital
Squarespace initiated with a Sector Perform at RBC Capital
06/07/21 Morgan Stanley
Global-e Online initiated with an Overweight at Morgan Stanley
06/07/21 Jefferies
Global-e Online initiated with a Buy at Jefferies
06/02/21 Truist
Affirm price target raised to $82 from $77 at Truist
SHOP Shopify
$1,247.70 /

+14.17 (+1.15%)

  • 23
    Feb
  • 16
    Sep
SHOP Shopify
$1,247.70 /

+14.17 (+1.15%)

SHOP Shopify
$1,247.70 /

+14.17 (+1.15%)

SHOP Shopify
$1,247.70 /

+14.17 (+1.15%)

Hot Stocks
ALX Oncology announces updates on ASPEN-03, ASPEN-04 studies » 07:07
06/14/21
06/14
07:07
06/14/21
07:07
ALXO

ALX Oncology

$59.66 /

-1.25 (-2.05%)

, MRK

Merck

$75.62 /

+0.13 (+0.17%)

ALX Oncology (ALXO)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALXO ALX Oncology
$59.66 /

-1.25 (-2.05%)

MRK Merck
$75.62 /

+0.13 (+0.17%)

ALXO ALX Oncology
$59.66 /

-1.25 (-2.05%)

05/04/21 Credit Suisse
ALX Oncology assumed with an Outperform at Credit Suisse
04/26/21 Credit Suisse
ALX Oncology assumed with an Outperform at Credit Suisse
04/06/21 UBS
ALX Oncology initiated with a Buy at UBS
03/05/21 Piper Sandler
ALX Oncology collab provides pipeline expansion opportunity, says Piper Sandler
MRK Merck
$75.62 /

+0.13 (+0.17%)

06/11/21 Morgan Stanley
Organon initiated with an Equal Weight at Morgan Stanley
06/10/21 Evercore ISI
Organon initiated with an Outperform at Evercore ISI
06/09/21 JPMorgan
Merck price target lowered to $100 from $105 at JPMorgan
06/07/21 Truist
Merck price target lowered to $93 from $96 at Truist
ALXO ALX Oncology
$59.66 /

-1.25 (-2.05%)

MRK Merck
$75.62 /

+0.13 (+0.17%)

  • 13
    Jan
  • 10
    Dec
  • 17
    Jul
MRK Merck
$75.62 /

+0.13 (+0.17%)

MRK Merck
$75.62 /

+0.13 (+0.17%)

ALXO ALX Oncology
$59.66 /

-1.25 (-2.05%)

MRK Merck
$75.62 /

+0.13 (+0.17%)

Earnings
Kaleyra sees Q2 revenue $50M- $51M, consensus $40.48M » 07:07
06/14/21
06/14
07:07
06/14/21
07:07
KLR

Kaleyra

$12.40 /

-0.16 (-1.27%)

Sees FY21 revenue $258M -…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KLR Kaleyra
$12.40 /

-0.16 (-1.27%)

KLR Kaleyra
$12.40 /

-0.16 (-1.27%)

06/11/21 Northland
Kaleyra price target raised to $29 from $23 at Northland
03/19/21 Northland
Kaleyra on track for 21% growth in Q1, says Northland
02/22/21 Maxim
Kaleyra price target raised to $42 from $30 at Maxim
02/17/21 Craig-Hallum
Kaleyra price target raised to $25 from $20 at Craig-Hallum
KLR Kaleyra
$12.40 /

-0.16 (-1.27%)

  • 25
    Jun
KLR Kaleyra
$12.40 /

-0.16 (-1.27%)

KLR Kaleyra
$12.40 /

-0.16 (-1.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.